Franklin Genomic AdvancementHELXETF
13F holders, Q2 2024 (June 30)7holders −3
1new positions
4sold out
$31.69avg. 13F price*
At the end of Q2 2024, 7 institutions reported holding Franklin Genomic Advancement (HELX) in their 13F filings, down 3 from Q1 2024. 1 opened new positions and 4 sold out. The largest holders were Glenview Trust Co ($1.0M), GTS Securities LLC ($874K) and LPL Financial LLC ($343K).
- Company
- Franklin Genomic Advancement
- CUSIP
- 35473P520
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 4 | $1.0M |
All 13F filers, Q1 2024 → Q2 2024: 15,526 shares bought and 32,385 shares sold, net −16,859 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Glenview Trust Co | 0.02% | No change | 32,625 | $1.0M |
| GTS Securities LLC | 0.02% | Add +101.4% | 27,603 | $874K |
| LPL Financial LLC | 0.00% | Add +17.2% | 10,823 | $343K |
| Commonwealth Equity Services, LLC | 0.00% | Reduce -5.2% | 6,677 | $212K |
| Harbour Investments, Inc. | 0.00% | No change | 188 | $6K |
| Osaic Holdings, Inc. | 0.00% | Reduce -38.0% | 184 | $6K |
| UBS Group AG | 0.00% | New | 42 | $1K |
"% of holder's portfolio" is HELX's weight in each manager's 13F, not the share of Franklin Genomic Advancement the manager owns.